LCD L36256: MolDX: Molecular Diagnostic Tests (MDT) — Noridian
Policy LCD-L36256 · Clinical Laboratory
New molecular diagnostics policy may impact billing processes.
Code intelligence
0040U reimbursement alerts
Policy changes, MAC LCD updates, and CMS guidance matched to code 0040U.
Elevated code riskDenied? See the governing policy
Signal breakdown
17 shown · 17 total in platform
Risk: Elevated
0
Critical
0%
8
High
47%
9
Routine
53%
0
Low
0%
New this month
—
alerts added in last 30 days
Effective soon
—
no upcoming deadlines
High
LCD L36021: MolDX: Molecular Diagnostic Tests (MDT) — CGS
Policy LCD-L36021 · Clinical Laboratory
New MolDX policy effective in 2025 may alter billing processes.
LCD L36117: MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease — CGS
Policy LCD-L36117 · Hematology
New genetic testing LCD affects billing for myeloproliferative disease.
LCD L36815: MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease — WPS
Policy LCD-L36815 · Hematology
New LCD impacts billing for myeloproliferative disease testing.
LCD L36180: MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease — Noridian
Policy LCD-L36180 · Hematology
New genetic testing guidelines announced by Noridian.
LCD L36044: MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease — Palmetto GBA
Policy LCD-L36044 · Hematology
New guidelines impact billing for genetic tests in myeloproliferative disease.
LCD L36186: MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease — Noridian
Policy LCD-L36186 · Hematology
Impact on genetic testing billing for myeloproliferative diseases.
LCD L35160: MolDX: Molecular Diagnostic Tests (MDT) — Noridian
Policy LCD-L35160 · Clinical Laboratory
New MolDX guidelines may alter MDT billing processes.
LCD L38814: MolDX: Minimal Residual Disease Testing for Cancer — Noridian
Policy LCD-L38814 · Oncology
Billing impact from new MolDX LCD for cancer tests.
LCD L39923: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — Noridian
Policy LCD-L39923 · Hematology
Changes in billing for myeloproliferative neoplasms testing ahead.
LCD L40022: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — WPS
Policy LCD-L40022 · Hematology
New LCD on non-NGS tests for myeloproliferative neoplasms.
LCD L39927: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — Noridian
Policy LCD-L39927 · Hematology
New LCD for myeloproliferative neoplasm testing impacts billing.
LCD L38835: MolDX: Minimal Residual Disease Testing for Cancer — WPS
Policy LCD-L38835 · Oncology
New LCD requires billing team review.
LCD L39919: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — Palmetto GBA
Policy LCD-L39919 · Hematology
New LCD may affect billing for specific myeloproliferative tests.
LCD L38816: MolDX: Minimal Residual Disease Testing for Cancer — Noridian
Policy LCD-L38816 · Oncology
Billing changes for cancer testing impact providers significantly.
LCD L40000: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — CGS
Policy LCD-L40000 · Hematology
New LCD impacts billing for myeloproliferative neoplasms testing.
LCD L38822: MolDX: Minimal Residual Disease Testing for Cancer — CGS
Policy LCD-L38822 · Oncology
Prepare for new billing guidelines in oncology testing.
Audit documentation
Building an audit file that includes 0040U?
The Tripwire Audit Pack exports 12 months of Clinical Laboratory policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Get the Clinical Laboratory audit pack — $349One-time purchase · not a subscription